about
Emerging drugs for Guillain-Barré syndromeGuillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosisIVIG treatment and prognosis in Guillain-Barré syndromeGuillain–Barré Syndrome—A Classical Autoimmune Disease Triggered by Infection or VaccinationOccupational exposure to swine, poultry, and cattle and antibody biomarkers of Campylobacter jejuni exposure and autoimmune peripheral neuropathyGuillain-barré syndrome following influenza vaccination: causal or coincidental?[Guillain-Barré syndrome after exposure to influenza].Neurologic indications for therapeutic plasma exchange: an update.Neurologic indications for therapeutic plasma exchange: 2011 update.Neurologic indications for therapeutic plasma exchange: 2013 update.Antibodies and brain disease: a convergence of immunology and physiology.Chemical validation of molecular mimicry: interaction of cholera toxin with Campylobacter lipooligosaccharides.An acute evolving flaccid quadriparesis in an elderly woman.Pathogenesis and treatment of immune-mediated neuropathies.Treatment guidelines for Guillain-Barré Syndrome.Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseasesAnti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy.Basic and clinical aspects of autoimmune disorders in peripheral nerves.Determination of glycolipid-protein interaction specificity.Host-pathogen interactions in Campylobacter infections: the host perspective.Anti-GM2 ganglioside antibodies are a biomarker for acute canine polyradiculoneuritis.Anti-ganglioside antibody-mediated activation of RhoA induces inhibition of neurite outgrowth.Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update.Early Electrodiagnostic Features of Upper Extremity Sensory Nerves Can Differentiate Axonal Guillain-Barré Syndrome from Acute Inflammatory Demyelinating Polyneuropathy.Losing your nerves? Maybe it's the antibodies.Electrophysiologic and immunopathologic correlates in Guillain-Barré syndrome subtypes.Treatment in inflammatory neuropathies.Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?Homeostatic regulation of the endoneurial microenvironment during development, aging and in response to trauma, disease and toxic insult.CIDP - the relevance of recent advances in Schwann cell/axonal neurobiology.Novel treatment for immune neuropathies on the horizon.Autoantobodies activate small GTPase RhoA to modulate neurite outgrowth.Pathophysiology of immune-mediated demyelinating neuropathies-part I: neuroscience.Pathophysiology and diagnosis of Guillain-Barré syndrome - challenges and needs.Antibody-mediated rejection of the heart in the setting of autoimmune demyelinating polyneuropathy: a case report and review of the literatureCorrelations between cytomegalovirus, Epstein-Barr virus, anti-ganglioside antibodies, electrodiagnostic findings and functional status in Guillain-Barré syndrome.Dissecting the Role of Anti-ganglioside Antibodies in Guillain-Barré Syndrome: an Animal Model Approach.The role of complement in neurological and neuropsychiatric diseases.Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment.Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study.
P2860
Q22241376-6507897D-E563-4C76-86B3-DE593C49FA15Q22251013-ED43CAB4-330F-4471-B6C0-3174D7254812Q22252627-DA1F6863-D469-4AAA-8E7F-028C800AD1BFQ24276196-175C17FD-17EB-49B5-9C09-09F56B187928Q28395659-CAD74F9F-8175-4CAC-8548-FCCD06746193Q30403959-10E6999E-6A1B-4498-B360-F8F97FFC0725Q30415924-3DB7B39F-CADF-4407-B2E9-E70289B768A1Q30454297-E4662645-C8FA-461B-9480-4909BCECA736Q30455391-E6B85C6F-F94B-4F14-83B0-C41A64F277B0Q30458271-49C96F0F-B0B8-4483-84E1-3B79E63B7E1EQ33267001-FA744AAF-8B49-41C6-90BD-D1A6D5CB165CQ33269357-84DE7E81-864A-4B5D-96B0-A42CFBD4D92CQ33364211-73C6AC9F-CFE7-49ED-A4E2-ADA8B769DD2CQ34409385-6F4E761C-1EB3-4E7B-AE8E-1BB498C14333Q35152989-A9AC3B6C-101B-4AF3-B044-6AFC3F18B113Q35220367-F2386E09-E6EC-4C26-AC75-F37F46E108D2Q35780245-959CC5AE-0B6B-4149-ABB6-98634B8ABEE2Q36459487-259F862C-4755-41E1-86D2-98E22E153C61Q36667119-D7910722-D43E-4CEA-9E5A-25313AC139F1Q36803887-DAA65F75-2CF0-44C2-A338-E0943AEDB482Q36862161-36ACF595-F240-4F95-B800-A03E6805C671Q37135577-862C6DE5-D05D-4966-A18E-BC9838B0EF3CQ37329516-65087020-CF0B-41F6-828F-BF34A2A717E8Q37338718-B355CFD4-E33A-437C-ABE2-538DBFAC9388Q37440005-C0BC6279-32BD-48E9-A3D5-9E976B890FDEQ37507978-8C28DBA6-9F58-4D3D-A4CC-DB6493693314Q37733512-B14BA794-5004-4070-B2A2-05F52B4031D5Q37782118-CD09588A-127D-4D51-91D3-399C09FB0590Q37817010-4078A634-2E6B-4CB7-9BA1-95C1C7F99BBBQ37866845-94B9DA43-E37E-4A8D-82D8-9FCB3138617BQ37892641-6B6C2717-251C-416E-8717-570BBB189405Q37965171-FEC56480-7110-4024-90A5-DC0D1F516D85Q38134344-E9DAE032-746F-4055-B322-E4DEBFBF708CQ38204498-E868FE5C-E0D5-473A-8480-CB9774203543Q38211647-FBAA5E6D-2DFF-4DE9-BB93-8182A082B643Q38544073-D0D900C0-8058-4D63-A2F6-B4DE16D20E8DQ38587703-2C253967-FFE6-4BA4-90C1-26D7B3CA4E71Q38590250-0181C1AC-D586-451F-9993-61AB1520DD56Q38862736-34A8EBBF-8B13-4DF6-84CF-0B66A8CA782BQ39227455-5090E874-A1BF-48CF-9E60-CD29BB7E0C69
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The immunobiology of Guillain-Barré syndromes.
@ast
The immunobiology of Guillain-Barré syndromes.
@en
type
label
The immunobiology of Guillain-Barré syndromes.
@ast
The immunobiology of Guillain-Barré syndromes.
@en
prefLabel
The immunobiology of Guillain-Barré syndromes.
@ast
The immunobiology of Guillain-Barré syndromes.
@en
P2860
P1476
The immunobiology of Guillain-Barré syndromes.
@en
P2093
Hugh J Willison
P2860
P304
P356
10.1111/J.1085-9489.2005.0010202.X
P577
2005-06-01T00:00:00Z